



ARTES and Basic Pharma near completion of their joint rHSA project

Geleen – Langenfeld, May 2024

ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer.

ARTES, a leading company that is specialized in developing and transferring recombinant cell lines and protein production processes from microbial expression systems, and Basic Pharma, a pharmaceutical company focusing on pharmaceutical products, are delighted to announce significant progress in their strategic collaboration to produce recombinant Human Serum Albumin derived from *Hansenula* yeast.

The teams have been working successfully on the development of rHSA and the project is on track to completion.

The release of the first vials containing rHSA are expected this summer as the project approaches the final stages of development. The target audience for the rHSA includes laboratories in academia and industry that require small quantities of high-quality recombinant proteins for their research endeavors.

Melanie Piontek, Business Development Director of ARTES, states: "This collaboration between two successful biotech companies co-marketing products needed in the life sciences has today established a new offering for researchers worldwide. We look forward to seeing this grow in the future." Michael Piontek, Managing Director of ARTES Biotechnology, added: "The combination of development and manufacturing capabilities at both ARTES and our partner Basic Pharma enables the launch of human albumin today and several new peptides and proteins in the near future."

Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his satisfaction with the progress; "This collaboration has been instrumental in realizing our vision of offering reagents for research applications. Our joint efforts with ARTES have paved the way for the release of Human Serum Albumin, marking a significant milestone in our strategic collaboration." Bob Kool, Managing Director at Basic Pharma, further emphasized: "The synergy between ARTES and Basic Pharma has been remarkable. We are excited about the potential impact of rHSA and are looking forward in this collaboration towards the development of pharmaceutical grade biologicals."

For more information please contact:

ARTES Biotechnology GmbH

Dr. Melanie Piontek

+49 2173 27587 12

melanie.piontek@artes-biotechnology.com

www.artes-biotechnology.biz

Basic Pharma Technologies BV

Dr. Ralph Bosmans

+31 (0) 88 255 4015

R.Bosmans@basicpharma.nl

www.basicpharma.nl



ARTES Biotechnology GmbH – www.artes-biotechnology.biz

ARTES Biotechnology GmbH is a Germany-based company specialized in development of recombinant protein production processes from microbial expression systems. The offer is particular in the development of optimized production cell lines and processes based on yeast (*Hansenula*, *Pichia*, *Saccharomyces*) and bacteria (*E. coli*). The expression platform is complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES partners successfully with human and animal health companies, enzyme manufacturer, the cosmetic, diagnostic and nutrition industry. Operation worldwide takes place from its 870 sqm facilities in Langenfeld.

Basic Pharma – www.basicpharma.nl

Basic Pharma is a pharmaceutical company focused on the development, production, licensing, and registration of pharmaceutical niche products. The company offers a range of services, including contract manufacturing, formulation development, regulatory support, and analytical services. Founded in 2003 and headquartered in Geleen, the Netherlands, Basic Pharma's products are sold worldwide. In 2020, Basic Pharma expanded its portfolio by inaugurating a dedicated biotechnology department focusing on the production of biologicals. This department is suitably equipped for microbial fermentation and protein purification, thereby facilitating the progression and production of recombinant proteins.